EDGAR Filing Documents for 0001654954-19-001122

Form 8-K - Current report:

SEC Accession No. 0001654954-19-001122

Filing Date

2019-02-06

Accepted

2019-02-06 16:00:32

Documents

Period of Report

2019-02-04

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	CURRENT REPORT	gtbp_8k.htm	8-K	39838
2	SECURED CONVERTIBLE NOTE	gtbp_ex41.htm	EX-4.1	170375
3	SECURITIES PURCHASE AGREEMENT	gtbp_ex101.htm	EX-10.1	295240
4	SECURITY AGREEMENT	gtbp_ex102.htm	EX-10.2	265712
5	REGISTRATION RIGHTS AGREEMENT	gtbp_ex103.htm	EX-10.3	191232
	Complete submission text file	0001654954-19-001122.txt		964037

Mailing Address 310 N. WESTLAKE BLVD. SUITE 206 WESTLAKE VILLAGE CA 91362

Business Address 310 N. WESTLAKE BLVD. SUITE 206 WESTLAKE VILLAGE CA 91362 (800) 304-9888

GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)